ESMO Congress 2022

Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine 

Standard second-line chemotherapy may benefit fit patients but efficacy is limited and new treatments are urgently needed

Numerically improved overall survival was shown with abemaciclib plus trastuzumab and fulvestrant in patients with advanced breast cancer

While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients. 

Different approaches are explored, showing good efficacy and mixed tolerability, but further studies are needed to assess their feasibility 

These results highlight the need to better investigate the mechanisms of action, define the optimal timing of administration and identify predictive biomarkers

In a phase I/II study, the combination treatment was tolerable in men who had progressed on one novel anti-androgen therapy

Encouraging efficacy data with anti-PD1 antibody in combination or as monotherapy

Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments